CORRELATION ANALYSIS BETWEEN LABORATORY IMMUNE AND METABOLIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA STAGES I AND II ALONG WITH HYPERTENSION AFTER TREATMENT

• Published in: Medit͡s︡inskai͡a︡ immunologii͡a Vol. 23; no. 4; pp. 737 - 742
• Main Authors: Bystrova, N. A., Shulginova, A. A., Konoplya, A. I.
• Format: Journal Article
• Language: English; Russian
• Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 19.10.2021
• Subjects: chronic cerebral ischemia; interrelationships of parameters of immunometabolic status
• ISSN: 1563-0625; 2313-741X
• DOI: 10.15789/1563-0625-CAB-1992

Determination of interrelationships between impairments of laboratory parameters of immune and metabolic status in patients with chronic cerebral ischemia of I-II stages was carried out. The study included 104 patients, of which 76 were female and 28 males, with CCI on the background of II degree hypertension, of which 52 patients were with stage I and 52 with stage II at the age of 50 ± 5 years. Also, clinical and laboratory parameters were studied in 22 healthy donors of the same age. Evaluation of clinical and laboratory data was carried out at the beginning of treatment and 2 weeks after its end. The sorption capacity of erythrocytes and the sorption capacity of the glycocalyx (SEG), the activity of lipid peroxidation processes, the state of the antioxidant system were determined in blood plasma and erythrocytes, the level of stable metabolites of nitric oxide (SMNO), neopterin, C-reactive protein, cytokines (TNFα, IL- 1β, IL-8, IFNγ, IL-18, G-CSF, IL-4, IL-10), immunoglobulins (IgM, IgG, IgA), complement system components (C3, C4, C5, C5А), the phagocytic and oxygen-dependent activity of polymorphonuclear blood leukocytes. Comparative assessment of the results of correlation, factorial and cluster analyzes for assessing the parameters of the immune and metabolic status in patients with stage I CCI revealed the most significant laboratory parameters necessary for determination in the clinic for objective assessment of the severity of immune and metabolic disorders: TNFα, IL-8, IL-10, SMNO and NEG. In patients with CCI stage II, to objectively assess the severity of immune and metabolic disorders, TNFα, IL-8, IL-17, IL-10, the phagocytic number of neutrophils and SEG are recommended.